Role of Chemokine Receptor4 (CXCR4) Expression in Acute Myelogenous Leukemia

Abstract

Acute myeloid leukemia (AML) is a hematopoietic clonal malignancy that is characterized by uncontrolled proliferation of hematopoietic stem cells (HSCs) and progenitors without the capacity to differentiate into mature cells. The treatment and prognosis of AML patients depend on accurate cytogenetic and genetic examinations. Despite the fact that various novel reagents have demonstrated clinical activities, long-term outcomes of AML patients remain poor, which is mainly due to resistance to chemotherapy and disease relapse post-chemotherapy. CXC chemokine receptor 4 (CXCR4) expression on acute myeloid leukemia (AML) cells correlated with stromal cell derived factor-1α (SDF-1α) and retained hematopoietic progenitors and leukemia cells within the bone marrow microenvironment.